Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer G Wilson

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
Scientific Reports|June 23, 2021
Prospective validation of an 11-gene mRNA host response score for mortality risk stratification in the intensive care unitAndrew R Moore, Jonasel Roque, Brian T Shaller, et al.
Journal of the American College of Emergency Physicians Open|June 18, 2024
Association between emergency department disposition and mortality in patients with COVID-19 acute respiratory distress syndromeKatie M Lebold, Andrew R Moore, Pablo A Sanchez, et al.
Critical Care Medicine|September 11, 2023
Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical TrialsAndrew R Moore, Shaun M Pienkos, Pratik Sinha, et al.
Plos One|December 26, 2025
Drivers of prognosis and clinical trajectories differ between COVID and non-COVID acute hypoxic respiratory failureShaun Pienkos, Andrew R Moore, Jonasel Roque, et al.
JCI Insight|July 25, 2020
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsisJennifer G Wilson, Laura J Simpson, Anne-Maud Ferreira, et al.
The Lancet. Respiratory Medicine|December 23, 2014
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trialJennifer G Wilson, Kathleen D Liu, Hanjing Zhuo, et al.
Annals of the American Thoracic Society|July 21, 2023
Right Ventricular Dysfunction Patterns among Patients with COVID-19 in the Intensive Care Unit: A Retrospective Cohort AnalysisPablo A Sanchez, Christian T O'Donnell, Nadia Francisco, et al.
Annals of Intensive Care|January 17, 2015
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndromeKathleen D Liu, Jennifer G Wilson, Hanjing Zhuo, et al.
MMWR. Morbidity and Mortality Weekly Report|July 3, 2020
Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May 2020Mark W Tenforde, Erica Billig Rose, Christopher J Lindsell, et al.
The Lancet. Respiratory Medicine|November 21, 2018
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trialMichael A Matthay, Carolyn S Calfee, Hanjing Zhuo, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Scientific Reports|June 23, 2021
Prospective validation of an 11-gene mRNA host response score for mortality risk stratification in the intensive care unitAndrew R Moore, Jonasel Roque, Brian T Shaller, et al.
Journal of the American College of Emergency Physicians Open|June 18, 2024
Association between emergency department disposition and mortality in patients with COVID-19 acute respiratory distress syndromeKatie M Lebold, Andrew R Moore, Pablo A Sanchez, et al.
Critical Care Medicine|September 11, 2023
Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical TrialsAndrew R Moore, Shaun M Pienkos, Pratik Sinha, et al.
Plos One|December 26, 2025
Drivers of prognosis and clinical trajectories differ between COVID and non-COVID acute hypoxic respiratory failureShaun Pienkos, Andrew R Moore, Jonasel Roque, et al.
JCI Insight|July 25, 2020
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsisJennifer G Wilson, Laura J Simpson, Anne-Maud Ferreira, et al.
The Lancet. Respiratory Medicine|December 23, 2014
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trialJennifer G Wilson, Kathleen D Liu, Hanjing Zhuo, et al.
Annals of the American Thoracic Society|July 21, 2023
Right Ventricular Dysfunction Patterns among Patients with COVID-19 in the Intensive Care Unit: A Retrospective Cohort AnalysisPablo A Sanchez, Christian T O'Donnell, Nadia Francisco, et al.
Annals of Intensive Care|January 17, 2015
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndromeKathleen D Liu, Jennifer G Wilson, Hanjing Zhuo, et al.
MMWR. Morbidity and Mortality Weekly Report|July 3, 2020
Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May 2020Mark W Tenforde, Erica Billig Rose, Christopher J Lindsell, et al.
The Lancet. Respiratory Medicine|November 21, 2018
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trialMichael A Matthay, Carolyn S Calfee, Hanjing Zhuo, et al.
Pageof 9